Our proprietary medicinal chemistry and formulation technologies allow us to continue to design new and innovative medicines to treat CNS conditions. These technologies and capabilities include:

Chiral and Formulation Chemistry. Our AXS-09 product candidate was developed using our chiral chemistry and formulation capabilities to identify, isolate and stabilize chirally pure enantiomers.

Learn more about our science

MoSEIC™ Technology. Our AXS-06 and AXS-07 product candidates incorporate our MoSEIC™ technology which is designed to substantially increase the solubility and speed the absorption of target drug molecules.

Learn more about our science

Metabolic Inhibition Technology. Our AXS-05 and AXS-09 product candidates incorporate our technology of using metabolic inhibition as a novel drug delivery method to increase the bioavailability and prolong the half-life of target drug molecules.

Learn more about our science

Proprietary Synthesis and Analysis. Our AXS-02 product candidate was generated using proprietary chemical synthesis and analysis to increase the solubility and enable the oral delivery of the target drug molecule.